[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fv8-KxTQGwEeTuLYOVvQx3b7eLgyvkEL71v-H69uZlBE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"University of Turin, Italy",[4],206,false,19,30,59853,7,162,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Periodontitis",10,{"name":18,"count":19},"Periodontal Diseases",6,{"name":21,"count":22},"Multiple Myeloma",5,{"name":24,"count":25},"Respiratory Insufficiency",3,{"name":27,"count":25},"Sepsis",{"name":29,"count":25},"Diabetes Mellitus, Type 2",{"name":31,"count":25},"Shoulder Pain",{"name":33,"count":25},"Insulin Resistance",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05014581","Preventing Cardiovascular Collapse With Vasopressors During Tracheal Intubation","2026-03","Noradrenaline",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03829371","STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","2027-01-03","Velcade",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,82,100,118,136,154,172,196,223,247,274,292,318,346,364,389,441,466,492,510,528,553,578,603,629,653,677,695,713,731,749,773,791,814,840,858,883,908,933,951,976,999,1022,1040,1065,1083,1109,1137,1160,1186,1213,1231,1259,1285,1314,1332,1357,1384,1402,1430,1455,1481,1499,1525,1549,1575],{"intervention":44,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":65,"NA":80},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":58},[],{"trials":66,"activeCount":54,"soonestReadout":43},[67],{"nctId":41,"briefTitle":42,"status":68,"phases":69,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":74},"ACTIVE_NOT_RECRUITING",[50],"2030-01-03","2019-01-03",450,[21],[44,75,76,77,78,79],"Melphalan","Prednisone","Lenalidomide","Dexamethasone","Daratumumab",{"trials":81,"activeCount":58},[],{"intervention":75,"totalTrials":54,"cells":83},{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":98},{"trials":85,"activeCount":58},[],{"trials":87,"activeCount":58},[],{"trials":89,"activeCount":58},[],{"trials":91,"activeCount":58},[],{"trials":93,"activeCount":54,"soonestReadout":43},[94],{"nctId":41,"briefTitle":42,"status":68,"phases":95,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":96,"interventions":97},[50],[21],[44,75,76,77,78,79],{"trials":99,"activeCount":58},[],{"intervention":76,"totalTrials":54,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":116},{"trials":103,"activeCount":58},[],{"trials":105,"activeCount":58},[],{"trials":107,"activeCount":58},[],{"trials":109,"activeCount":58},[],{"trials":111,"activeCount":54,"soonestReadout":43},[112],{"nctId":41,"briefTitle":42,"status":68,"phases":113,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":114,"interventions":115},[50],[21],[44,75,76,77,78,79],{"trials":117,"activeCount":58},[],{"intervention":77,"totalTrials":54,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":134},{"trials":121,"activeCount":58},[],{"trials":123,"activeCount":58},[],{"trials":125,"activeCount":58},[],{"trials":127,"activeCount":58},[],{"trials":129,"activeCount":54,"soonestReadout":43},[130],{"nctId":41,"briefTitle":42,"status":68,"phases":131,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":132,"interventions":133},[50],[21],[44,75,76,77,78,79],{"trials":135,"activeCount":58},[],{"intervention":78,"totalTrials":54,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":146,"NA":152},{"trials":139,"activeCount":58},[],{"trials":141,"activeCount":58},[],{"trials":143,"activeCount":58},[],{"trials":145,"activeCount":58},[],{"trials":147,"activeCount":54,"soonestReadout":43},[148],{"nctId":41,"briefTitle":42,"status":68,"phases":149,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":150,"interventions":151},[50],[21],[44,75,76,77,78,79],{"trials":153,"activeCount":58},[],{"intervention":79,"totalTrials":54,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":170},{"trials":157,"activeCount":58},[],{"trials":159,"activeCount":58},[],{"trials":161,"activeCount":58},[],{"trials":163,"activeCount":58},[],{"trials":165,"activeCount":54,"soonestReadout":43},[166],{"nctId":41,"briefTitle":42,"status":68,"phases":167,"primaryCompletion":43,"completion":70,"start":71,"enrollment":72,"conditions":168,"interventions":169},[50],[21],[44,75,76,77,78,79],{"trials":171,"activeCount":58},[],{"intervention":39,"totalTrials":54,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":192,"NA":194},{"trials":175,"activeCount":58},[],{"trials":177,"activeCount":58},[],{"trials":179,"activeCount":58},[],{"trials":181,"activeCount":54,"soonestReadout":38},[182],{"nctId":36,"briefTitle":37,"status":183,"phases":184,"primaryCompletion":38,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":191},"RECRUITING",[49],"2026-04","2024-08-01",420,[189,190],"Critical Illness","Respiratory Failure",[39],{"trials":193,"activeCount":58},[],{"trials":195,"activeCount":58},[],{"intervention":197,"totalTrials":54,"cells":198},"Peg-Interferon alpha2a plus Ribavirin",{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":221},{"trials":200,"activeCount":58},[],{"trials":202,"activeCount":58},[],{"trials":204,"activeCount":58},[],{"trials":206,"activeCount":58},[],{"trials":208,"activeCount":58},[209],{"nctId":210,"briefTitle":211,"status":212,"phases":213,"primaryCompletion":214,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT00575627","Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels","UNKNOWN",[50],"2009-09","2010-09","2007-09",150,[219],"Chronic Hepatitis C",[197],{"trials":222,"activeCount":58},[],{"intervention":224,"totalTrials":54,"cells":225},"metformin",{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":245},{"trials":227,"activeCount":58},[],{"trials":229,"activeCount":58},[],{"trials":231,"activeCount":58},[],{"trials":233,"activeCount":58},[],{"trials":235,"activeCount":58},[236],{"nctId":237,"briefTitle":238,"status":212,"phases":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT00370617","Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance",[50],"2009-01","2006-09",200,[219,33],[224],{"trials":246,"activeCount":58},[],{"intervention":248,"totalTrials":54,"cells":249},"Xalatan+Cosopt",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":272},{"trials":251,"activeCount":58},[],{"trials":253,"activeCount":58},[],{"trials":255,"activeCount":58},[],{"trials":257,"activeCount":58},[],{"trials":259,"activeCount":58},[260],{"nctId":261,"briefTitle":262,"status":212,"phases":263,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":268,"interventions":270},"NCT00796198","Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure",[50],"2009-06","2009-07","2008-12",50,[269],"Glaucoma",[248,271],"Xalatan",{"trials":273,"activeCount":58},[],{"intervention":271,"totalTrials":54,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":58},[],{"trials":279,"activeCount":58},[],{"trials":281,"activeCount":58},[],{"trials":283,"activeCount":58},[],{"trials":285,"activeCount":58},[286],{"nctId":261,"briefTitle":262,"status":212,"phases":287,"primaryCompletion":264,"completion":265,"start":266,"enrollment":267,"conditions":288,"interventions":289},[50],[269],[248,271],{"trials":291,"activeCount":58},[],{"intervention":293,"totalTrials":54,"cells":294},"Anti-CD20 antibodies",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":316},{"trials":296,"activeCount":58},[],{"trials":298,"activeCount":58},[],{"trials":300,"activeCount":58},[],{"trials":302,"activeCount":58},[],{"trials":304,"activeCount":58},[305],{"nctId":306,"briefTitle":307,"status":308,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT06680349","Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis","COMPLETED",[50],"2024-01-02","2022-12-01",21,[314],"Fibrillary Glomerulonephritis",[293],{"trials":317,"activeCount":58},[],{"intervention":319,"totalTrials":54,"cells":320},"Arginine",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":344},{"trials":322,"activeCount":58},[],{"trials":324,"activeCount":58},[],{"trials":326,"activeCount":58},[],{"trials":328,"activeCount":58},[],{"trials":330,"activeCount":58},[331],{"nctId":332,"briefTitle":333,"status":334,"phases":335,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":342},"NCT00569465","N-Acetylcysteine and Arginine Administration in Diabetic Patients","TERMINATED",[50],"2006-01","2005-01",24,[340,341],"Type 2 Diabetes Mellitus","Hypertension",[319,343],"Acetylcysteine",{"trials":345,"activeCount":58},[],{"intervention":343,"totalTrials":54,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":354,"PHASE4":356,"NA":362},{"trials":349,"activeCount":58},[],{"trials":351,"activeCount":58},[],{"trials":353,"activeCount":58},[],{"trials":355,"activeCount":58},[],{"trials":357,"activeCount":58},[358],{"nctId":332,"briefTitle":333,"status":334,"phases":359,"completion":336,"start":337,"enrollment":338,"conditions":360,"interventions":361},[50],[340,341],[319,343],{"trials":363,"activeCount":58},[],{"intervention":365,"totalTrials":54,"cells":366},"Eptifibatide",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":375,"NA":387},{"trials":368,"activeCount":58},[],{"trials":370,"activeCount":58},[],{"trials":372,"activeCount":58},[],{"trials":374,"activeCount":58},[],{"trials":376,"activeCount":58},[377],{"nctId":378,"briefTitle":379,"status":334,"phases":380,"primaryCompletion":381,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT01454440","The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)",[50],"2009-10","2007-10",91,[385],"Coronary Artery Disease",[365],{"trials":388,"activeCount":58},[],{"intervention":390,"totalTrials":391,"cells":392},"Docetaxel",2,{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":399,"PHASE4":437,"NA":439},{"trials":394,"activeCount":58},[],{"trials":396,"activeCount":58},[],{"trials":398,"activeCount":58},[],{"trials":400,"activeCount":58},[401,414],{"nctId":402,"briefTitle":403,"status":212,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":411},"NCT01224405","Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy",[49],"2010-08","2016-04","2010-04",600,[410],"Advanced Prostate Cancer",[412,390,390,413,413],"Docetaxel + LH-RH analogues","Continuous Docetaxel",{"nctId":415,"briefTitle":416,"status":212,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":432},"NCT03402048","The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial",[49],"2020-12","2021-05","2012-07",567,[423,424,425,426,427,428,429,430,431],"Stage IV, NSCLC","Lung Neoplasms","Bronchial Neoplasms","Carcinoma, Bronchogenic","Lung Diseases","Neoplasms","Respiratory Tract Diseases","Respiratory Tract Neoplasms","Thoracic Neoplasms",[433,434,435,390,436],"Carboplatin","Gemcitabine","Pemetrexed","Vinorelbine",{"trials":438,"activeCount":58},[],{"trials":440,"activeCount":58},[],{"intervention":442,"totalTrials":54,"cells":443},"maraviroc",{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":462,"NA":464},{"trials":445,"activeCount":58},[],{"trials":447,"activeCount":58},[],{"trials":449,"activeCount":58},[],{"trials":451,"activeCount":58},[452],{"nctId":453,"briefTitle":454,"status":455,"phases":456,"primaryCompletion":457,"completion":457,"start":458,"enrollment":58,"conditions":459,"interventions":461},"NCT03708861","Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients","WITHDRAWN",[49],"2017-12","2016-01",[460],"HIV Infection",[442],{"trials":463,"activeCount":58},[],{"trials":465,"activeCount":58},[],{"intervention":467,"totalTrials":54,"cells":468},"Loop Diuretics",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":475,"PHASE4":488,"NA":490},{"trials":470,"activeCount":58},[],{"trials":472,"activeCount":58},[],{"trials":474,"activeCount":58},[],{"trials":476,"activeCount":58},[477],{"nctId":478,"briefTitle":479,"status":308,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":487},"NCT03592836","Diuretic Response in Advanced Heart Failure: Bolus Intermittent vs Continuous INfusion",[49],"2017-12-22","2013-05-01",80,[485,486],"Heart Failure NYHA Class III","Heart Failure NYHA Class IV",[467],{"trials":489,"activeCount":58},[],{"trials":491,"activeCount":58},[],{"intervention":412,"totalTrials":54,"cells":493},{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":506,"NA":508},{"trials":495,"activeCount":58},[],{"trials":497,"activeCount":58},[],{"trials":499,"activeCount":58},[],{"trials":501,"activeCount":58},[502],{"nctId":402,"briefTitle":403,"status":212,"phases":503,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":504,"interventions":505},[49],[410],[412,390,390,413,413],{"trials":507,"activeCount":58},[],{"trials":509,"activeCount":58},[],{"intervention":413,"totalTrials":54,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":524,"NA":526},{"trials":513,"activeCount":58},[],{"trials":515,"activeCount":58},[],{"trials":517,"activeCount":58},[],{"trials":519,"activeCount":58},[520],{"nctId":402,"briefTitle":403,"status":212,"phases":521,"primaryCompletion":405,"completion":406,"start":407,"enrollment":408,"conditions":522,"interventions":523},[49],[410],[412,390,390,413,413],{"trials":525,"activeCount":58},[],{"trials":527,"activeCount":58},[],{"intervention":529,"totalTrials":54,"cells":530},"N-acetylcysteine",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":549,"NA":551},{"trials":532,"activeCount":58},[],{"trials":534,"activeCount":58},[],{"trials":536,"activeCount":58},[],{"trials":538,"activeCount":58},[539],{"nctId":540,"briefTitle":541,"status":308,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT01082445","Effects of N-acetylcysteine on Diabetic Foot Oxygenation",[49],"2010-11","2009-08",100,[547],"Foot Ulcer, Diabetic",[529],{"trials":550,"activeCount":58},[],{"trials":552,"activeCount":58},[],{"intervention":554,"totalTrials":54,"cells":555},"Vitamin C",{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":562,"PHASE4":574,"NA":576},{"trials":557,"activeCount":58},[],{"trials":559,"activeCount":58},[],{"trials":561,"activeCount":58},[],{"trials":563,"activeCount":58},[564],{"nctId":565,"briefTitle":566,"status":334,"phases":567,"completion":568,"start":569,"enrollment":483,"conditions":570,"interventions":573},"NCT00387114","Effect of an Anti-Oxidant Treatment on Resistin Serum Levels.A Randomized Study",[49],"2005-11","2005-06",[571,572],"Metabolic Diseases","Oxidative Stress",[554],{"trials":575,"activeCount":58},[],{"trials":577,"activeCount":58},[],{"intervention":579,"totalTrials":54,"cells":580},"Interferon Beta 1",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":599,"NA":601},{"trials":582,"activeCount":58},[],{"trials":584,"activeCount":58},[],{"trials":586,"activeCount":58},[],{"trials":588,"activeCount":58},[589],{"nctId":590,"briefTitle":591,"status":308,"phases":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":598},"NCT00473213","Optimizing IFN Beta - 1B Dose",[49],"2004-02","1999-09",217,[597],"Multiple Sclerosis",[579],{"trials":600,"activeCount":58},[],{"trials":602,"activeCount":58},[],{"intervention":604,"totalTrials":54,"cells":605},"Belimumab",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":612,"PHASE4":625,"NA":627},{"trials":607,"activeCount":58},[],{"trials":609,"activeCount":58},[],{"trials":611,"activeCount":58},[],{"trials":613,"activeCount":58},[614],{"nctId":615,"briefTitle":616,"status":212,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT05020782","The BeLimumab Antiphospholipid Syndrome Trial (BLAST)",[48,49],"2024-10-01","2025-01-01","2022-06-01",15,[623],"Antiphospholipid Syndrome",[604],{"trials":626,"activeCount":58},[],{"trials":628,"activeCount":58},[],{"intervention":630,"totalTrials":54,"cells":631},"Sucrose solution 30%1 ml",{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":638,"PHASE4":649,"NA":651},{"trials":633,"activeCount":58},[],{"trials":635,"activeCount":58},[],{"trials":637,"activeCount":58},[],{"trials":639,"activeCount":58},[640],{"nctId":641,"briefTitle":642,"status":308,"phases":643,"completion":644,"start":645,"enrollment":545,"conditions":646,"interventions":648},"NCT00482560","Analgesic Effect of Breast Feeding vs Sucrose in Neonatal Screening",[49],"2007-04","2007-01",[647],"Pain",[630],{"trials":650,"activeCount":58},[],{"trials":652,"activeCount":58},[],{"intervention":654,"totalTrials":54,"cells":655},"MITOTANE",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":673,"NA":675},{"trials":657,"activeCount":58},[],{"trials":659,"activeCount":58},[],{"trials":661,"activeCount":58},[],{"trials":663,"activeCount":58},[664],{"nctId":665,"briefTitle":666,"status":212,"phases":667,"primaryCompletion":668,"completion":418,"start":669,"enrollment":242,"conditions":670,"interventions":672},"NCT00777244","Efficacy of Adjuvant Mitotane Treatment (ADIUVO)",[49],"2018-12","2008-04",[671],"Adrenocortical Carcinoma",[654],{"trials":674,"activeCount":58},[],{"trials":676,"activeCount":58},[],{"intervention":433,"totalTrials":54,"cells":678},{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":691,"NA":693},{"trials":680,"activeCount":58},[],{"trials":682,"activeCount":58},[],{"trials":684,"activeCount":58},[],{"trials":686,"activeCount":58},[687],{"nctId":415,"briefTitle":416,"status":212,"phases":688,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":689,"interventions":690},[49],[423,424,425,426,427,428,429,430,431],[433,434,435,390,436],{"trials":692,"activeCount":58},[],{"trials":694,"activeCount":58},[],{"intervention":434,"totalTrials":54,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":709,"NA":711},{"trials":698,"activeCount":58},[],{"trials":700,"activeCount":58},[],{"trials":702,"activeCount":58},[],{"trials":704,"activeCount":58},[705],{"nctId":415,"briefTitle":416,"status":212,"phases":706,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":707,"interventions":708},[49],[423,424,425,426,427,428,429,430,431],[433,434,435,390,436],{"trials":710,"activeCount":58},[],{"trials":712,"activeCount":58},[],{"intervention":435,"totalTrials":54,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":727,"NA":729},{"trials":716,"activeCount":58},[],{"trials":718,"activeCount":58},[],{"trials":720,"activeCount":58},[],{"trials":722,"activeCount":58},[723],{"nctId":415,"briefTitle":416,"status":212,"phases":724,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":725,"interventions":726},[49],[423,424,425,426,427,428,429,430,431],[433,434,435,390,436],{"trials":728,"activeCount":58},[],{"trials":730,"activeCount":58},[],{"intervention":436,"totalTrials":54,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":745,"NA":747},{"trials":734,"activeCount":58},[],{"trials":736,"activeCount":58},[],{"trials":738,"activeCount":58},[],{"trials":740,"activeCount":58},[741],{"nctId":415,"briefTitle":416,"status":212,"phases":742,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":743,"interventions":744},[49],[423,424,425,426,427,428,429,430,431],[433,434,435,390,436],{"trials":746,"activeCount":58},[],{"trials":748,"activeCount":58},[],{"intervention":750,"totalTrials":54,"cells":751},"Terlipressin",{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":758,"PHASE4":769,"NA":771},{"trials":753,"activeCount":58},[],{"trials":755,"activeCount":58},[],{"trials":757,"activeCount":58},[],{"trials":759,"activeCount":58},[760],{"nctId":761,"briefTitle":762,"status":308,"phases":763,"primaryCompletion":216,"completion":216,"start":241,"enrollment":764,"conditions":765,"interventions":767},"NCT00370253","Noradrenalin vs Terlipressin in Hepatorenal Syndrome",[49],20,[766],"Hepatorenal Syndrome",[750,768],"Noradrenalin",{"trials":770,"activeCount":58},[],{"trials":772,"activeCount":58},[],{"intervention":768,"totalTrials":54,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":787,"NA":789},{"trials":776,"activeCount":58},[],{"trials":778,"activeCount":58},[],{"trials":780,"activeCount":58},[],{"trials":782,"activeCount":58},[783],{"nctId":761,"briefTitle":762,"status":308,"phases":784,"primaryCompletion":216,"completion":216,"start":241,"enrollment":764,"conditions":785,"interventions":786},[49],[766],[750,768],{"trials":788,"activeCount":58},[],{"trials":790,"activeCount":58},[],{"intervention":792,"totalTrials":54,"cells":793},"Paclitaxel",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":808,"PHASE4":810,"NA":812},{"trials":795,"activeCount":58},[],{"trials":797,"activeCount":58},[],{"trials":799,"activeCount":58},[800],{"nctId":801,"briefTitle":802,"status":212,"phases":803,"primaryCompletion":381,"completion":804,"start":669,"enrollment":9,"conditions":805,"interventions":806},"NCT00786110","Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients",[48],"2010-10",[671],[807,792],"Sorafenib",{"trials":809,"activeCount":58},[],{"trials":811,"activeCount":58},[],{"trials":813,"activeCount":58},[],{"intervention":815,"totalTrials":54,"cells":816},"letrozolo+cyclophosphamide",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":818,"activeCount":58},[],{"trials":820,"activeCount":58},[],{"trials":822,"activeCount":58},[823],{"nctId":824,"briefTitle":825,"status":212,"phases":826,"primaryCompletion":827,"completion":828,"start":216,"enrollment":829,"conditions":830,"interventions":832},"NCT00954135","Letrozole Plus Oral Cyclophosphamide Plus\u002FMinus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients",[48],"2010-06","2010-12",190,[831],"Breast Cancer",[815,833],"letrozolo+sorafenib+cyclophosphamide",{"trials":835,"activeCount":58},[],{"trials":837,"activeCount":58},[],{"trials":839,"activeCount":58},[],{"intervention":833,"totalTrials":54,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":843,"activeCount":58},[],{"trials":845,"activeCount":58},[],{"trials":847,"activeCount":58},[848],{"nctId":824,"briefTitle":825,"status":212,"phases":849,"primaryCompletion":827,"completion":828,"start":216,"enrollment":829,"conditions":850,"interventions":851},[48],[831],[815,833],{"trials":853,"activeCount":58},[],{"trials":855,"activeCount":58},[],{"trials":857,"activeCount":58},[],{"intervention":859,"totalTrials":54,"cells":860},"sildenafil",{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":862,"activeCount":58},[],{"trials":864,"activeCount":58},[],{"trials":866,"activeCount":58},[867],{"nctId":868,"briefTitle":869,"status":308,"phases":870,"primaryCompletion":871,"completion":872,"start":873,"enrollment":764,"conditions":874,"interventions":876},"NCT01481350","Sildenafil for Post-capillary Pulmonary Hypertension in Patients Undergoing Cardiac Surgery",[48],"2013-06","2013-12","2012-02",[875],"Pulmonary Hypertension",[859],{"trials":878,"activeCount":58},[],{"trials":880,"activeCount":58},[],{"trials":882,"activeCount":58},[],{"intervention":884,"totalTrials":54,"cells":885},"Niraparib",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":887,"activeCount":58},[],{"trials":889,"activeCount":58},[],{"trials":891,"activeCount":58},[892],{"nctId":893,"briefTitle":894,"status":308,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT03945084","Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy",[48],"2021-09-01","2019-08-27",58,[900],"Urothelial Carcinoma",[884],{"trials":903,"activeCount":58},[],{"trials":905,"activeCount":58},[],{"trials":907,"activeCount":58},[],{"intervention":909,"totalTrials":54,"cells":910},"hydrocortisone",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":912,"activeCount":58},[],{"trials":914,"activeCount":58},[],{"trials":916,"activeCount":58},[917],{"nctId":918,"briefTitle":919,"status":212,"phases":920,"primaryCompletion":266,"completion":921,"start":922,"enrollment":267,"conditions":923,"interventions":925},"NCT00657306","Adrenal Insufficiency in Cirrhotics With Ascites. Effects of Hydrocortisone on Renal and Haemodynamic Function",[48],"2009-05","2008-05",[924],"Cirrhosis With Ascites",[909,926],"dextrose solution 5%",{"trials":928,"activeCount":58},[],{"trials":930,"activeCount":58},[],{"trials":932,"activeCount":58},[],{"intervention":926,"totalTrials":54,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":936,"activeCount":58},[],{"trials":938,"activeCount":58},[],{"trials":940,"activeCount":58},[941],{"nctId":918,"briefTitle":919,"status":212,"phases":942,"primaryCompletion":266,"completion":921,"start":922,"enrollment":267,"conditions":943,"interventions":944},[48],[924],[909,926],{"trials":946,"activeCount":58},[],{"trials":948,"activeCount":58},[],{"trials":950,"activeCount":58},[],{"intervention":952,"totalTrials":54,"cells":953},"Pembrolizumab Injectable Product",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":955,"activeCount":58},[],{"trials":957,"activeCount":58},[],{"trials":959,"activeCount":58},[960],{"nctId":961,"briefTitle":962,"status":212,"phases":963,"primaryCompletion":964,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT03379441","Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC",[48],"2023-01-01","2018-01-01",126,[968],"Non Small Cell Lung Cancer Patients",[952],{"trials":971,"activeCount":58},[],{"trials":973,"activeCount":58},[],{"trials":975,"activeCount":58},[],{"intervention":977,"totalTrials":54,"cells":978},"Revlimid",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":980,"activeCount":58},[],{"trials":982,"activeCount":58},[],{"trials":984,"activeCount":58},[985],{"nctId":986,"briefTitle":987,"status":308,"phases":988,"completion":989,"start":337,"enrollment":990,"conditions":991,"interventions":992},"NCT00396045","Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma",[47,48],"2008-01",54,[21],[977],{"trials":994,"activeCount":58},[],{"trials":996,"activeCount":58},[],{"trials":998,"activeCount":58},[],{"intervention":1000,"totalTrials":54,"cells":1001},"THALIDOMIDE",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1003,"activeCount":58},[],{"trials":1005,"activeCount":58},[],{"trials":1007,"activeCount":58},[1008],{"nctId":1009,"briefTitle":1010,"status":308,"phases":1011,"completion":266,"start":1012,"enrollment":9,"conditions":1013,"interventions":1014},"NCT00358020","Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients",[48],"2004-11",[21],[1000,1015],"BORTEZOMIB",{"trials":1017,"activeCount":58},[],{"trials":1019,"activeCount":58},[],{"trials":1021,"activeCount":58},[],{"intervention":1015,"totalTrials":54,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":58},[],{"trials":1027,"activeCount":58},[],{"trials":1029,"activeCount":58},[1030],{"nctId":1009,"briefTitle":1010,"status":308,"phases":1031,"completion":266,"start":1012,"enrollment":9,"conditions":1032,"interventions":1033},[48],[21],[1000,1015],{"trials":1035,"activeCount":58},[],{"trials":1037,"activeCount":58},[],{"trials":1039,"activeCount":58},[],{"intervention":1041,"totalTrials":54,"cells":1042},"albumin 4 gr\u002FL ascites removed",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1044,"activeCount":58},[],{"trials":1046,"activeCount":58},[],{"trials":1048,"activeCount":58},[1049],{"nctId":1050,"briefTitle":1051,"status":212,"phases":1052,"primaryCompletion":266,"completion":266,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1057},"NCT00428506","Albumin 4 gr\u002FL vs 8 gr\u002FL in the Prevention of Post-Paracentesis Circulatory Dysfunction",[48],"2007-02",70,[1056],"Tense Ascites in Cirrhosis",[1041,1058],"albumin 8 gr\u002FL ascites removed",{"trials":1060,"activeCount":58},[],{"trials":1062,"activeCount":58},[],{"trials":1064,"activeCount":58},[],{"intervention":1058,"totalTrials":54,"cells":1066},{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1077,"PHASE4":1079,"NA":1081},{"trials":1068,"activeCount":58},[],{"trials":1070,"activeCount":58},[],{"trials":1072,"activeCount":58},[1073],{"nctId":1050,"briefTitle":1051,"status":212,"phases":1074,"primaryCompletion":266,"completion":266,"start":1053,"enrollment":1054,"conditions":1075,"interventions":1076},[48],[1056],[1041,1058],{"trials":1078,"activeCount":58},[],{"trials":1080,"activeCount":58},[],{"trials":1082,"activeCount":58},[],{"intervention":1084,"totalTrials":54,"cells":1085},"niraparib and dostarlimab",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1103,"PHASE4":1105,"NA":1107},{"trials":1087,"activeCount":58},[],{"trials":1089,"activeCount":58},[],{"trials":1091,"activeCount":58},[1092],{"nctId":1093,"briefTitle":1094,"status":212,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1054,"conditions":1099,"interventions":1102},"NCT04940637","UNITO-001- Study in HRR\u002FPDL1 Positive MPM\u002FNSCLC",[48],"2024-06-30","2025-06-30","2020-12-23",[1100,1101],"Lung Cancer","Mesothelioma",[1084],{"trials":1104,"activeCount":58},[],{"trials":1106,"activeCount":58},[],{"trials":1108,"activeCount":58},[],{"intervention":1110,"totalTrials":54,"cells":1111},"Cetuximab-IRDye800",{"EARLY_PHASE1":1112,"PHASE1":1114,"PHASE2":1116,"PHASE3":1131,"PHASE4":1133,"NA":1135},{"trials":1113,"activeCount":58},[],{"trials":1115,"activeCount":58},[],{"trials":1117,"activeCount":58},[1118],{"nctId":1119,"briefTitle":1120,"status":212,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1130},"NCT06101394","Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules",[48],"2025-07","2025-12","2024-01",25,[1100,1127,1128,1129],"Video-assisted Thoracic Surgery","EGFR","Cetuximab",[1110],{"trials":1132,"activeCount":58},[],{"trials":1134,"activeCount":58},[],{"trials":1136,"activeCount":58},[],{"intervention":1138,"totalTrials":54,"cells":1139},"bevacizumab + octreotide LAR + capecitabine",{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1141,"activeCount":58},[],{"trials":1143,"activeCount":58},[],{"trials":1145,"activeCount":58},[1146],{"nctId":1147,"briefTitle":1148,"status":212,"phases":1149,"primaryCompletion":921,"completion":828,"start":336,"enrollment":1150,"conditions":1151,"interventions":1153},"NCT01203306","Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors",[48],42,[1152],"Neuroendocrine Carcinomas",[1138],{"trials":1155,"activeCount":58},[],{"trials":1157,"activeCount":58},[],{"trials":1159,"activeCount":58},[],{"intervention":1161,"totalTrials":54,"cells":1162},"continuous 5 fluouracil infusion plus long-acting octreotide",{"EARLY_PHASE1":1163,"PHASE1":1165,"PHASE2":1167,"PHASE3":1180,"PHASE4":1182,"NA":1184},{"trials":1164,"activeCount":58},[],{"trials":1166,"activeCount":58},[],{"trials":1168,"activeCount":58},[1169],{"nctId":1170,"briefTitle":1171,"status":308,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":1176,"conditions":1177,"interventions":1179},"NCT00953394","5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors",[48],"2006-02","2006-12","2002-02",29,[1178],"Neuroendocrine Tumors",[1161],{"trials":1181,"activeCount":58},[],{"trials":1183,"activeCount":58},[],{"trials":1185,"activeCount":58},[],{"intervention":1187,"totalTrials":54,"cells":1188},"VR_Training_1PP",{"EARLY_PHASE1":1189,"PHASE1":1203,"PHASE2":1205,"PHASE3":1207,"PHASE4":1209,"NA":1211},{"trials":1190,"activeCount":58},[1191],{"nctId":1192,"briefTitle":1193,"status":212,"phases":1194,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":1198,"conditions":1199,"interventions":1201},"NCT05364970","IVR in Motor Rehabilitation",[46],"2025-04-01","2025-12-01","2023-04-12",45,[1200],"Knee Injuries",[1187,1202],"VR_Training_3PP",{"trials":1204,"activeCount":58},[],{"trials":1206,"activeCount":58},[],{"trials":1208,"activeCount":58},[],{"trials":1210,"activeCount":58},[],{"trials":1212,"activeCount":58},[],{"intervention":1202,"totalTrials":54,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1229},{"trials":1216,"activeCount":58},[1217],{"nctId":1192,"briefTitle":1193,"status":212,"phases":1218,"primaryCompletion":1195,"completion":1196,"start":1197,"enrollment":1198,"conditions":1219,"interventions":1220},[46],[1200],[1187,1202],{"trials":1222,"activeCount":58},[],{"trials":1224,"activeCount":58},[],{"trials":1226,"activeCount":58},[],{"trials":1228,"activeCount":58},[],{"trials":1230,"activeCount":58},[],{"intervention":807,"totalTrials":391,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1234,"activeCount":58},[],{"trials":1236,"activeCount":58},[],{"trials":1238,"activeCount":58},[1239],{"nctId":801,"briefTitle":802,"status":212,"phases":1240,"primaryCompletion":381,"completion":804,"start":669,"enrollment":9,"conditions":1241,"interventions":1242},[48],[671],[807,792],{"trials":1244,"activeCount":58},[],{"trials":1246,"activeCount":58},[],{"trials":1248,"activeCount":58},[1249],{"nctId":1250,"briefTitle":1251,"status":212,"phases":1252,"primaryCompletion":405,"completion":1253,"start":827,"enrollment":1254,"conditions":1255,"interventions":1258},"NCT01230697","Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)",[],"2011-09",60,[1256,1257],"Kidney Cancer","Liver Cancer",[807],{"intervention":1260,"totalTrials":54,"cells":1261},"Corifollitropin Alfa",{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1270,"NA":1272},{"trials":1263,"activeCount":58},[],{"trials":1265,"activeCount":58},[],{"trials":1267,"activeCount":58},[],{"trials":1269,"activeCount":58},[],{"trials":1271,"activeCount":58},[],{"trials":1273,"activeCount":58},[1274],{"nctId":1275,"briefTitle":1276,"status":308,"phases":1277,"primaryCompletion":1278,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT03816670","Prospective Randomized Trial Comparing Corifollitropin-alfa Late Start vs. Corifollitropin-alfa Standard Start in Expected Poor, Normal and High-responders Undergoing IVF",[51],"2018-04-30","2018-12-31","2017-04-01",113,[1283],"Fertility Disorders",[1260],{"intervention":1286,"totalTrials":54,"cells":1287},"iron sulphate",{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1296,"NA":1298},{"trials":1289,"activeCount":58},[],{"trials":1291,"activeCount":58},[],{"trials":1293,"activeCount":58},[],{"trials":1295,"activeCount":58},[],{"trials":1297,"activeCount":58},[],{"trials":1299,"activeCount":58},[1300],{"nctId":1301,"briefTitle":1302,"status":308,"phases":1303,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1312},"NCT01507792","Iron Repletion in Chronic Cough and Iron Deficiency",[51],"2011-01","2002-01",22,[1308,1309,1310,1311],"Cough","Laryngeal Disease","Bronchial Disease","Iron Deficiency",[1286,1313],"antiH1-histamine, proton pump inhibitor",{"intervention":1313,"totalTrials":54,"cells":1315},{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1317,"activeCount":58},[],{"trials":1319,"activeCount":58},[],{"trials":1321,"activeCount":58},[],{"trials":1323,"activeCount":58},[],{"trials":1325,"activeCount":58},[],{"trials":1327,"activeCount":58},[1328],{"nctId":1301,"briefTitle":1302,"status":308,"phases":1329,"primaryCompletion":1304,"completion":1304,"start":1305,"enrollment":1306,"conditions":1330,"interventions":1331},[51],[1308,1309,1310,1311],[1286,1313],{"intervention":1333,"totalTrials":54,"cells":1334},"Anti-CD38 Monoclonal Antibody",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1336,"activeCount":58},[],{"trials":1338,"activeCount":58},[],{"trials":1340,"activeCount":58},[],{"trials":1342,"activeCount":58},[],{"trials":1344,"activeCount":58},[],{"trials":1346,"activeCount":58},[1347],{"nctId":1348,"briefTitle":1349,"status":308,"phases":1350,"primaryCompletion":310,"completion":1351,"start":1352,"enrollment":1353,"conditions":1354,"interventions":1356},"NCT06571864","AL Amyloidosis and Anti-CD38-Daratunumab",[51],"2024-02-02","2022-01-02",14,[1355],"Amyloidosis",[1333],{"intervention":1358,"totalTrials":54,"cells":1359},"CBT + OLANZAPINE",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1361,"activeCount":58},[],{"trials":1363,"activeCount":58},[],{"trials":1365,"activeCount":58},[],{"trials":1367,"activeCount":58},[],{"trials":1369,"activeCount":58},[],{"trials":1371,"activeCount":58},[1372],{"nctId":1373,"briefTitle":1374,"status":308,"phases":1375,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":1378,"conditions":1379,"interventions":1382},"NCT01990755","Neurobiology of Eating Disorders Treatments",[51],"2013-05","2010-05",112,[1380,1381],"Anorexia Nervosa","Bulimia Nervosa",[1358,1383],"delorazepam",{"intervention":1383,"totalTrials":54,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1387,"activeCount":58},[],{"trials":1389,"activeCount":58},[],{"trials":1391,"activeCount":58},[],{"trials":1393,"activeCount":58},[],{"trials":1395,"activeCount":58},[],{"trials":1397,"activeCount":58},[1398],{"nctId":1373,"briefTitle":1374,"status":308,"phases":1399,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":1378,"conditions":1400,"interventions":1401},[51],[1380,1381],[1358,1383],{"intervention":1403,"totalTrials":54,"cells":1404},"oral cholecalciferol",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1406,"activeCount":58},[],{"trials":1408,"activeCount":58},[],{"trials":1410,"activeCount":58},[],{"trials":1412,"activeCount":58},[],{"trials":1414,"activeCount":58},[],{"trials":1416,"activeCount":58},[1417],{"nctId":1418,"briefTitle":1419,"status":308,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1429},"NCT02661191","Vitamin D Deficiency and Asthma Exacerbation",[51],"2013-03","2014-03","2012-10",119,[1426,1427,1428],"Asthma","Vitamin D Deficiency","Disease Exacerbation",[1403],{"intervention":1431,"totalTrials":54,"cells":1432},"Intravenous pain medication",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1434,"activeCount":58},[],{"trials":1436,"activeCount":58},[],{"trials":1438,"activeCount":58},[],{"trials":1440,"activeCount":58},[],{"trials":1442,"activeCount":58},[],{"trials":1444,"activeCount":58},[1445],{"nctId":1446,"briefTitle":1447,"status":308,"phases":1448,"primaryCompletion":1449,"completion":1450,"start":1451,"enrollment":217,"conditions":1452,"interventions":1454},"NCT02645058","RIRS Versus ESWL for the Treatment of Renal Stones",[51],"2018-05-30","2019-06-19","2015-03-02",[1453],"Renal Stones",[1431],{"intervention":1456,"totalTrials":54,"cells":1457},"rFSH plus rLH",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1466,"NA":1468},{"trials":1459,"activeCount":58},[],{"trials":1461,"activeCount":58},[],{"trials":1463,"activeCount":58},[],{"trials":1465,"activeCount":58},[],{"trials":1467,"activeCount":58},[],{"trials":1469,"activeCount":58},[1470],{"nctId":1471,"briefTitle":1472,"status":308,"phases":1473,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":1477,"interventions":1479},"NCT02322398","Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization",[],"2014-08","2010-03",848,[1478],"Infertility",[1456,1480],"hMG",{"intervention":1480,"totalTrials":54,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1489,"PHASE4":1491,"NA":1493},{"trials":1484,"activeCount":58},[],{"trials":1486,"activeCount":58},[],{"trials":1488,"activeCount":58},[],{"trials":1490,"activeCount":58},[],{"trials":1492,"activeCount":58},[],{"trials":1494,"activeCount":58},[1495],{"nctId":1471,"briefTitle":1472,"status":308,"phases":1496,"primaryCompletion":1474,"completion":1474,"start":1475,"enrollment":1476,"conditions":1497,"interventions":1498},[],[1478],[1456,1480],{"intervention":1500,"totalTrials":54,"cells":1501},"SGLT2 inhibitor",{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1503,"activeCount":58},[],{"trials":1505,"activeCount":58},[],{"trials":1507,"activeCount":58},[],{"trials":1509,"activeCount":58},[],{"trials":1511,"activeCount":58},[],{"trials":1513,"activeCount":58},[1514],{"nctId":1515,"briefTitle":1516,"status":212,"phases":1517,"primaryCompletion":1518,"completion":1519,"start":1520,"enrollment":9,"conditions":1521,"interventions":1524},"NCT03917758","Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors",[51],"2020-07-30","2020-10-30","2018-10-10",[29,1522,1523],"Arterial Hypertension","Body Weight Changes",[1500],{"intervention":1526,"totalTrials":54,"cells":1527},"MethylPREDNISolone Acetate 40 MG\u002FML",{"EARLY_PHASE1":1528,"PHASE1":1530,"PHASE2":1532,"PHASE3":1534,"PHASE4":1536,"NA":1538},{"trials":1529,"activeCount":58},[],{"trials":1531,"activeCount":58},[],{"trials":1533,"activeCount":58},[],{"trials":1535,"activeCount":58},[],{"trials":1537,"activeCount":58},[],{"trials":1539,"activeCount":58},[1540],{"nctId":1541,"briefTitle":1542,"status":308,"phases":1543,"primaryCompletion":1422,"completion":1544,"start":1421,"enrollment":764,"conditions":1545,"interventions":1548},"NCT03652480","Shoulder Corticosteroid Injection in Diabetic Patients",[],"2014-09-30",[31,1546,1547],"Corticosteroid Injection","Type2 Diabetes Mellitus",[1526],{"intervention":1550,"totalTrials":54,"cells":1551},"Oral antibiotic drugs",{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1553,"activeCount":58},[],{"trials":1555,"activeCount":58},[],{"trials":1557,"activeCount":58},[],{"trials":1559,"activeCount":58},[],{"trials":1561,"activeCount":58},[],{"trials":1563,"activeCount":58},[1564],{"nctId":1565,"briefTitle":1566,"status":308,"phases":1567,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":1571,"interventions":1573},"NCT04438655","Prospective Randomized Clinical Trial on Oral and Intravenous Antibiotic Prophylaxis in Colorectal Surgery.",[51],"2021-11-01","2019-05-01",130,[1572],"Colorectal Surgery",[1550,1574],"Parenteral prophylaxis",{"intervention":1574,"totalTrials":54,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1578,"activeCount":58},[],{"trials":1580,"activeCount":58},[],{"trials":1582,"activeCount":58},[],{"trials":1584,"activeCount":58},[],{"trials":1586,"activeCount":58},[],{"trials":1588,"activeCount":58},[1589],{"nctId":1565,"briefTitle":1566,"status":308,"phases":1590,"primaryCompletion":1568,"completion":1568,"start":1569,"enrollment":1570,"conditions":1591,"interventions":1592},[51],[1572],[1550,1574]]